Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Catalyst Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Catalyst Pharmaceuticals Inc’s stock price such as:

• Catalyst Pharmaceuticals Inc’s current stock price and volume
• Why Catalyst Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for CPRX from analysts
• CPRX’s stock price momentum as measured by its relative strength

About Catalyst Pharmaceuticals Inc (CPRX)

Before we jump into Catalyst Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Want to learn more about Catalyst Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc’s Stock Price as of Market Close

As of May 29, 2024, 4:00 PM, CST, Catalyst Pharmaceuticals Inc’s stock price was $15.88.

Catalyst Pharmaceuticals Inc is down 4.16% from its previous closing price of $16.57.

During the last market session, Catalyst Pharmaceuticals Inc’s stock traded between $15.97 and $16.60. Currently, there are 116.81 million shares of Catalyst Pharmaceuticals Inc stock available for purchase.

Catalyst Pharmaceuticals Inc’s price-earnings (P/E) ratio is currently at 30.8, which is high compared to the Pharmaceuticals industry median of 22.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Catalyst Pharmaceuticals Inc Stock Price History

Catalyst Pharmaceuticals Inc’s (CPRX) price is currently up 5.52% so far this month.

During the month of May, Catalyst Pharmaceuticals Inc’s stock price has reached a high of $17.03 and a low of $14.47.

Over the last year, Catalyst Pharmaceuticals Inc has hit prices as high as $17.50 and as low as $11.09. Year to date, Catalyst Pharmaceuticals Inc’s stock is down 14.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Catalyst Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 28, 2024, there were 2 analysts who downgraded Catalyst Pharmaceuticals Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Catalyst Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Catalyst Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Catalyst Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Catalyst Pharmaceuticals Inc (CPRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Catalyst Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 28, 2024, Catalyst Pharmaceuticals Inc has a weighted four-quarter relative price strength of 4.79%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how Catalyst Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Catalyst Pharmaceuticals Inc Stock Price: Bottom Line

As of May 29, 2024, Catalyst Pharmaceuticals Inc’s stock price is $15.88, which is down 4.16% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Catalyst Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.